EndoGastric Solutions, a medical technology company focused on acid reflux, has closed a $45 million financing round to grow the reach of its non-invasive treatment. The Series I round includes $30.5 million in funding that was announced last summer as well as a $14.5 million investment from Accelmed, a medical device investor.
The company has raised around $251M million since launching in 2003. Prior investors include Advanced Technology Ventures (ATV), Canaan Partners, Canepa Healthcare, Chicago Growth Partners, CRG, Radius Ventures and Sightline Partners, among others.
The company is targeting GERD, also known as gastroesophageal reflux disease, which is a severe and chronic form of acid reflux. More than 60 million Americans experience acid reflux at least once a month, according to the American College of Gastroenterology.
